Alerts will be sent to your verified email
Verify Email
WOCKPHARMA
|
Wockhardt
|
Astrazeneca Pharma I
|
Pfizer
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
10.6 % | 18.6 % | 4.8 % |
|
R&D as a % of Total Sales
|
4.4 % | 0.0 | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
-3.51 % | 17.42 % | 19.03 % |
|
5yr average Equity Multiplier
|
2.02 | 1.99 | 1.25 |
|
5yr Average Asset Turnover Ratio
|
0.39 | 0.91 | 0.6 |
|
5yr Avg Net Profit Margin
|
-4.28 % | 9.65 % | 26.04 % |
|
Price to Book
|
5.02 | 28.36 | 6.06 |
|
P/E
|
0.0 | 113.76 | 27.79 |
|
5yr Avg Cash Conversion Cycle
|
-94.15 Days | -6.33 Days | 21.86 Days |
|
Inventory Days
|
61.29 Days | 68.19 Days | 49.93 Days |
|
Days Receivable
|
60.36 Days | 35.81 Days | 29.1 Days |
|
Days Payable
|
251.45 Days | 187.52 Days | 77.28 Days |
|
5yr Average Interest Coverage Ratio
|
-0.43 | 142.38 | 185.18 |
|
5yr Avg ROCE
|
-0.28 % | 23.84 % | 23.84 % |
|
5yr Avg Operating Profit Margin
|
5.03 % | 14.57 % | 31.72 % |
|
5 yr average Debt to Equity
|
0.56 | 0.0 | 0.0 |
|
5yr CAGR Net Profit
|
n/a | 4.4 % | 76.68 % |
|
5yr Average Return on Assets
|
-1.79 % | 8.92 % | 15.25 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
49.08 % | 75.0 % | 63.92 % |
|
Share Pledged by Promoters
|
21.3 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-14.75 % | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
7.86 % | 3.91 % | 5.23 % |
|
Wockhardt
|
Astrazeneca Pharma I
|
Pfizer
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|